InspireMD completed the full exercise of its underwriters’ option, adding about $5.3 million in proceeds to a stock-and-warrant offering that closed earlier in November. The two closings brought proceeds to approximately $40.2 million after underwriting discounts and before offering expenses.
The financing included common shares, pre-funded warrants and warrants that give holders the right to buy additional common shares. Those securities provide capital now, while the warrants create the possibility of further share issuance if exercised.
Key details
- The initial offering closed on November 16 and raised about $34.9 million in proceeds after underwriting discounts and before expenses.
- In that offering, InspireMD sold 7,342,308 common shares and pre-funded warrants covering up to 50.35 million additional shares. It also issued Series L warrants to purchase up to 43,269,231 shares.
- Underwriters had a 30-day option to buy additional shares and/or warrants on the same terms. They exercised the option in full, and the additional offering closed on November 20.
- The option covered up to 8,635,846 common shares and warrants to purchase up to 6,490,384 shares. The additional closing raised approximately $5.3 million after underwriting discounts and before offering expenses.
- The additional warrants are to be issued through an agreement with Securities Transfer Corporation, which will act as warrant agent.
Plain-English implications
The financing increases InspireMD’s capital, while the common shares add to the shares outstanding. The pre-funded warrants and the two sets of common-stock warrants could add further shares if exercised; the announcement does not specify their exercise prices or the proceeds the company might receive from future exercises.
